{"version":"1.0","provider_name":"Site da Brakke Consulting","provider_url":"https:\/\/brakkeconsulting.com\/pt","title":"News from Brakke Consulting","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"GXyBwrLwBF\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-october-20-2023\/\">Mirante de Brakke 20 de outubro de 2023<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-october-20-2023\/embed\/#?secret=GXyBwrLwBF\" width=\"600\" height=\"338\" title=\"&#8220;Brakke Viewpoint October 20, 2023&#8221; &#8212; Brakke Consulting Website\" data-secret=\"GXyBwrLwBF\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/brakkeconsulting.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>","description":"Two items in the newsletter today strengthened my excitement for monoclonal antibodies in veterinary medicine.\u00a0 With Zoetis now shipping Librela, the monoclonal antibody for pain in dogs, and Merck receiving conditional approval by the USDA\u2019s CVB for their oncology product for dogs, gilvetmab, it seems like our industry should be excited.\u00a0 Why? First, it shows that animal health companies can and will bring new and innovative drug technologies to the veterinary market.\u00a0 The market wants them and is willing to pay for them (think Cytopoint and Solensia, both from Zoetis).\u00a0 Secondly, innovation is also great for the sales and marketing teams of animal health companies \u2013 it gives them new products to detail and should help deliver better medicines to veterinarians and outcomes for pet owners.\u00a0 Third, because monoclonal antibodies are injected, rather than given orally, this will drive pets into clinics more frequently and will help keep the veterinarian and the veterinary technicians in the middle of the relationship between the pet and the pet owner. We know from the results of our Sales Force Effectiveness Study that veterinarians really do differentiate animal health companies based on their ability to bring innovative products and services to them.\u00a0 Our data shows that innovation is a driver of overall company performance and overall trust in the company.\u00a0 We are clearly excitedView Full Post;"}